- Investing Ideas
- South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
Results
8
Companies which are potentially undervalued and in an acceptable financial position.
8 companies
Dong-A Socio Holdings
Market Cap: ₩544.2b
Engages in the pharmaceutical business in South Korea.
A000640
₩82,100.00
7D
6.5%
1Y
-30.1%
Hugel
Market Cap: ₩2.9t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩270,000.00
7D
6.3%
1Y
-28.4%
Dong-A ST
Market Cap: ₩337.4b
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
A170900
₩35,100.00
7D
4.8%
1Y
-25.5%
Daewoong Pharmaceutical
Market Cap: ₩1.4t
Develops, manufactures and commercializes pharmaceutical products in South Korea and internationally.
A069620
₩124,500.00
7D
11.6%
1Y
-21.6%
PharmaResearch
Market Cap: ₩3.7t
Operates as a biopharmaceutical company primarily in South Korea.
A214450
₩360,500.00
7D
11.8%
1Y
-27.8%
Hanmi Pharm
Market Cap: ₩5.5t
A biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally.
A128940
₩436,000.00
7D
10.7%
1Y
48.6%
Medy-Tox
Market Cap: ₩517.5b
Operates as a biopharmaceutical company in South Korea.
A086900
₩79,400.00
7D
0.9%
1Y
-54.3%
ST PharmLtd
Market Cap: ₩2.7t
Provides manufacturing services for active pharmaceutical ingredient and intermediate.
A237690
₩129,700.00
7D
5.9%
1Y
47.4%